Table 2.
Clinical characteristics of participants
| Asthma (n = 93) | COPD (n = 116) | Total (n = 209) | |
|---|---|---|---|
| Stable /AE status | |||
| AE (%) | 10 (10.8) | 24 (20.9) | 34 (16.3) |
| Stable (%) | 83 (89.2) | 91 (79.1) | 174 (83.7) |
| Newly diagnosed/follow-up patients | |||
| Newly-diagnosed (%) | 41 (44.1) | 36 (31.0) | 77 (36.8) |
| Follow-up (%) | 52 (55.9) | 80 (69.0) | 132 (63.2) |
| Number of acute exacerbations in the past year | |||
| 0 (%) | 75 (80.6) | 82 (70.7) | 157 (75.1) |
| 1 (%) | 10 (10.8) | 18 (15.5) | 28 (13.4) |
| 2 (%) | 3 (3.2) | 7 (6.0) | 10 (4.8) |
| ≥ 3 (%) | 5 (5.4) | 9 (7.8) | 14 (6.7) |
| Pulmonary function | |||
| FEV1 (L), mean ± SD | 2.3 ± 0.8 | 1.4 ± 0.6 | 1.8 ± 0.8 |
| FEV1, %predicted, mean ± SD | 81.5 ± 21.4 | 51.7 ± 22.0 | 65.5 ± 26.3 |
| FEV1/FVC, mean ± SD | 74.4 ± 10.9 | 55.7 ± 11.6 | 64.3 ± 14.6 |
| PEF (L), mean ± SD | 5.9 ± 1.9 | 4.0 ± 1.8 | 4.9 ± 2.1 |
| IC (L), mean ± SD | 2.3 ± 0.6 | 2.0 ± 0.7 | 2.1 ± 0.7 |
| RV/TLC, mean ± SD | 43.1 ± 9.0 | 51.0 ± 9.8 | 47.3 ± 10.2 |
| GOLD | |||
| I (%) | / | 12 (14.5) | / |
| II (%) | / | 23 (27.7) | / |
| III (%) | / | 36 (43.4) | / |
| IV (%) | / | 12 (14.5) | / |
| Severity of asthma | |||
| Mild and moderate asthma (%) | 86 (92.5) | / | / |
| Severe asthma (%) | 7 (7.5) | / | / |
| Control of asthma | |||
| Well and partly controlled (%) | 83 (89.2) | / | / |
| Uncontrolled (%) | 10 (10.8) | / | / |
| CAT, mean ± SD | / | 10.5 ± 6.5 | / |
| mMRC, mean ± SD | 0.4 ± 0.7 | 1.2 ± 1.0 | 0.8 ± 0.9 |
Data are shown as means ± standard deviation or number (%) patients
COPD, chronic obstructive pulmonary disease; AE, acute exacerbation; FEV1, forced expiratory volume in 1 s; FEV1%, FEV1/predicted FEV1; FEV1/FVC, forced expiratory volume in 1 s/forced vital capacity; PEF, peak expiratory flow; IC, inspiratory capacity; RV/TLC, residual volume/total lung capacity; GOLD, Global initiative for Chronic Obstructive Lung Disease; CAT, COPD Assessment Test; mMRC, Medical Research Council Dyspnea Scale